Carrillo ER, de la Torre LT, Rosales AO

Idioma: Español
Referencias bibliográficas: 33
Paginas: 14-25
Archivo PDF: 215.14 Kb.

RESUMEN

El choque séptico es una de las principales causas de muerte en la unidad de cuidados críticos y es un problema de salud pública. La respuesta inflamatoria sistémica descontrolada desempeña un papel crítico en la patogenia de la sepsis y del choque séptico. El desequilibrio de los mecanismos que controlan la coagulación e inflamación favorecen el desarrollo de coagulación intravascular diseminada. La interacción entre la inflamación y la coagulación es la pieza clave de la patogénesis de la sepsis y el choque séptico. La trombomodulina, proteína C, trombina y el receptor endotelial de la proteína C (TM-PC-T-REPC) forman un complejo en la superficie del endotelio que mantiene el microambiente endotelial en un estado antiinflamatorio y anticoagulante.
El objetivo de este trabajo es revisar el papel crítico que tiene el complejo TM-PC-T-REPC en la interacción entre inflamación y coagulación en sepsis y el uso de la trombomodulina recombinante como una nueva alternativa terapéutica para el manejo de la sepsis grave y el choque séptico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Carrillo ER , Carrillo CJ, Carrillo CL. Manejo de la sepsis con paquetes terapéuticos de la Campaña para Incrementar la Supervivencia en Sepsis. Med Int Mex 2008;24:43-45.

2. Esmon C, Fukudome K, Mather T, Bode W, Regan L, Stearns-Kurosawa D et al. Inflammation, sepsis and coagulation. Haematologica 1999; 84:254-259.

3. Esmon N, Owen W, Esmon C. Isolation of a membranebound cofactor for thrombin catalized activation of protein C. J Biol Chem 1982;257:859-864.

4. Esmon C, Owen W. Identification of an endothelial cofactor for thrombin-catalized activation of protein C. Pro Nat Acad Scid 1981;78:2249-2252.

5. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Marumaya I, Zushi M. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1891-1897.

6. Salem H, Marumaya I, Marejus P. Isolation and characterization of thrombomodulin from human placenta. J Biol Chem 1984;259:12246-12251.

7. Fink L, Eidt J, Johnson K, Cook J, Cook C, Morser J et al. Thrombomodulin activity and localization. Int J Dev Biol 1993;37:221-226.

8. Van de Wouwer M, Conway M, Novel functions of thrombomodulin in inflammation. Crit Care Med 2004;32:254- 261.

9. Okamosto T, Tanigami H, Shimaoka M. Thrombomodulin: a bifunctional Modulator of Inflammation and Coagulation in Sepsis. Crit Care Res Pract 2012;ID 614545.

10. Yi H, Cheng K, Guey S, Hua W. The role of thrombomodulin lectin-like domain in inflammation. J Biom Sci 2012;19:34-39.

11. Esmon C, Esmon N, Harris K. Complex formation between thrombin and thrombomodulin inhibits both thrombin- catalized fibrin formation and factor V activation. J Biol Chem 1982;257:7944-7997.

12. Esmon C. The Protein C Pathway. Chest 2003;124:26–32

13. Lorente J. El Sistema De La Proteína C En La Sepsis. Med Intensiva 2003;27:171-173.

14. Arqueros V, Velasco F. El papel de la vía de la proteína C en la inflamacion: Implicaciones terapéuticas. Hematologica 2011;96:43-48.

15. Joyce E, Gelbert L, Ciaccia A, DeHoff B, Grinnell B. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-11203.

16. Franscini N, Bachli E, Blau N. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 2004;110:2903-2909.

17. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005;280:19808-19814.

18. Cao C, Gao Y, Li Y. The efficacy of activated protein C in murine endotoxemia is dependen ton integrin CD11b. J Clin Invest 2010;120:1971-1980.

19. Liu D, Cheng T, Guo H. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383.

20. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178-3184.

21. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 2000;76:2024- 2029.

22. Fukudome K, Kurosawa S, Stearns-Kurosawa J. The endothelial cell protein C receptor: cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996;271:17491-17498.

23. Stearns-Kurosawa J, Kurosawa S, Mollica J. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci 1996;93:10212-10216.

24. Conway M, Van de Wouwer S, Pollefeyt E. The lectinlike domain of thrombomodulin confers protection from neutrophil mediated tissue damage by suppressing adhesion molecule expression via nuclear factor B and mitogen activated protein kinase pathways. J Exp Med 2002; 196:565–577.

25. Esmon N, Carroll R Esmon C. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983;258:12238–12242.

26. Hofsteenge R, Taguchi H, Stone S. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Bioch Journal 1986;237:243– 251.

27. Tsiang S, Lentz R, Sadler E. Functional domains of membrane bound human thrombomodulin. J Biol Chem 1992; 267:6164–6170.

28. Villoutreix B, Dahlback B. Molecular model for the Ctype lectin domain of human thrombomodulin. J Mol Model 1998;4:310-322

29. Weisel J, Nagaswami C, Young T, Light D. The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem 1996;271: 31485-31490

30. Conway E. Thrombomodulin and its role in inflammation. Sem Immunopathol 2012;34:107-125.

31. Semeraro N, Ammollo C, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012;129: 290-295.

32. Faust S, Heyderman S, Levin M. Coagulation in severe sepsis: a central role for thromomodulin and activated protein C. Crit Care Med 2001;29:62-68

33. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy And Safety Of Recombinant Human Soluble Thrombomodulin (Art-123) In Disseminated Intravascular Coagulation: Results Of A Phase III, Randomized, Double-Blind Clinical Trial. Thromb Haemost 2012;5:31–34